136153-00-9Relevant academic research and scientific papers
Rhodium (I)-catalyzed cyclizations of 3-C-alkenyl pentodialdose derivatives
Gable,Benz
, p. 3473 - 3476 (1991)
Cyclization of 1,2-isopropylidene 3-C-allyl ribo-pentodialdose, and 1-methylallyl and 3-C-vinyl analogs, with [(Ph3P)2RhCl]2 under CH2CH2 leads to intramolecular hydroacylation of the alkene with sele
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
Quiroz, Ryan V.,Reutershan, Michael H.,Schneider, Sebastian E.,Sloman, David,Lacey, Brian M.,Swalm, Brooke M.,Yeung, Charles S.,Gibeau, Craig,Spellman, Daniel S.,Rankic, Danica A.,Chen, Dapeng,Witter, David,Linn, Doug,Munsell, Erik,Feng, Guo,Xu, Haiyan,Hughes, Jonathan M. E.,Lim, Jongwon,Saurí, Josep,Geddes, Kristin,Wan, Murray,Mansueto, My Sam,Follmer, Nicole E.,Fier, Patrick S.,Siliphaivanh, Phieng,Daublain, Pierre,Palte, Rachel L.,Hayes, Robert P.,Lee, Sandra,Kawamura, Shuhei,Silverman, Steven,Sanyal, Sulagna,Henderson, Timothy J.,Ye, Yingchun,Gao, Yuanwei,Nicholson, Benjamin,Machacek, Michelle R.
, p. 3911 - 3939 (2021/05/04)
Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational symmetric dimethylation of protein substrates. PRMT5 plays a critical role in regulating biological processes including transcriptio
PRMT5 INHIBITORS
-
Page/Page column 71-73; 90; 92, (2020/03/02)
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
Synthesis of the sugar building block of bicyclo-RNA
Haziri, Arben I.,Silhar, Peter,Renneberg, Dorte,Leumann, Christian J.
experimental part, p. 823 - 827 (2010/10/02)
We present the novel synthesis of two sugar units that are central intermediates for the formation of members of the bicyclo-DNA and -RNA family. The synthesis starts from commercially available 1,2:5,6-di-O-isopropylidene- α-D-glucofuranose. The key step involves the elaboration of a carbocyclic ring in a furanoside by rhodium(I)-catalyzed hydroacylation. Via this pathway, one of the sugar units is available in 8 steps and in an overall yield of 27%, while its deoxy derivative is obtained in 11 steps, which is 5 steps fewer than in our previous synthesis of this compound. Georg Thieme Verlag Stuttgart.
